PLIANT THERAPEUTICS INC. - COMMON STOCK

Pliant Therapeutics Presentations at The Liver Meeting® 2023 Highlight Bexotegrast, an Inhibitor of αvß6 and αvß1 Integrins, in Primary Sclerosing Cholangitis

13 Nov 2023 16:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results

09 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

08 Nov 2023 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer Highlight PLN-101095, A Novel Inhibitor of Integrins αvβ8 and αvβ1

06 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Three Presentations at the Annual Meeting of the Society for Immunotherapy of Cancer

31 Oct 2023 16:03:07 By Nasdaq GlobeNewswire

Pliant Therapeutics INTEGRIS-PSC Phase 2a Interim Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in an Oral Late-Breaking Presentation at The Liver Meeting® 2023

19 Oct 2023 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Appoints S. Mishima Gerhart as Chief Regulatory Officer

16 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Safety and Exploratory Efficacy Data from Phase 2a INTEGRIS-PSC Clinical Trial of Bexotegrast in Patients with Primary Sclerosing Cholangitis and Suspected Liver Fibrosis

26 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Host Investor Call and Webcast to Discuss Interim Results from INTEGRIS-PSC, a Phase 2a Trial in Patients with Primary Sclerosing Cholangitis

25 Sep 2023 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Presentations at the European Respiratory Society International Congress 2023

11 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Conferences

30 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Three Upcoming Presentations at the European Respiratory Society International Congress 2023

28 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results

09 Aug 2023 16:03:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Initiation of BEACON-IPF, a Phase 2b Clinical Trial of Bexotegrast in Idiopathic Pulmonary Fibrosis

09 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Association for the Study of the Liver (EASL) International Liver Congress™

23 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Presents Data from its Bexotegrast Program at the American Thoracic Society International Conference

24 May 2023 08:00:01 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in Upcoming Investor Events

10 May 2023 08:05:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results

09 May 2023 16:02:00 By Nasdaq GlobeNewswire

Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-IPF Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Durable Improvement Shown in FVC and Across Multiple Measures

30 Apr 2023 14:10:28 By Nasdaq GlobeNewswire

Pliant Therapeutics to Participate in the 22nd Annual Needham Healthcare Conference

12 Apr 2023 08:01:00 By Nasdaq GlobeNewswire